+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cardiac Biomarkers - Global Market Trajectory & Analytics

  • ID: 834989
  • Report
  • April 2021
  • Region: Global
  • 177 Pages
  • Global Industry Analysts, Inc
Global Cardiac Biomarkers Market to Reach $10.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Cardiac Biomarkers estimated at US$6.2 Billion in the year 2020, is projected to reach a revised size of US$10.8 Billion by 2027, growing at a CAGR of 8.1% over the period 2020-2027. Laboratory Testing, one of the segments analyzed in the report, is projected to record 7.7% CAGR and reach US$6.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Point-of-Care Testing segment is readjusted to a revised 8.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.7 Billion, While China is Forecast to Grow at 12.2% CAGR

The Cardiac Biomarkers market in the U.S. is estimated at US$1.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2027 trailing a CAGR of 12.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Select Competitors (Total 39 Featured):
  • Abbott Diagnostics
  • Beckman Coulter Inc.
  • BG Medicine
  • bioMérieux SA
  • Boditech Med Inc.
  • Labsystems Diagnostics OY
  • LifeSign LLC
  • LSI Medience Corp.
  • Merck KGaA
  • Ortho-Clinical Diagnostics Inc.
  • Quidel Corporation
  • Randox Laboratories
  • Response Biomedical Corp.
  • Roche Diagnostics Corp.
  • Siemens Healthineers
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • A Curtain Raiser
  • Major Cardiac Markers and their Properties
  • Recent Market Activity
  • Market Set to Record Strong Growth Led by Advancements in Cardiac Biomarker Combinations
  • North America Corners Biggest Slice, Asia-Pacific to Dictate Market Momentum
  • Laboratory Testing Remains Gold Standard, POC Testing Rapidly Gains Traction
  • Analysis by Type of Cardiac Biomarker Assay/Test
  • Competitive Landscape
  • Intense Competition among Players in the Cardiac Diagnostics Market
  • Leading Vendors Focus on Curtailing Turnaround Time of POC Cardiac Testing Kits
  • Cardiac Markers Point-Of-Care Testing (POC) Cardiac Testing Segment: Major Players and their Operating Brands
  • Other Recent Innovations
  • Lipid Biomarker Panel to Detect HfrEF
  • VectraplexECG System with CEB® Cardiac Electrical Biomarker
  • Cardiac Biomarkers on Smartphone
  • Stringent Regulations and Other Challenges
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
  • Abbott Diagnostics, Inc. (USA)
  • Quidel Corporation (USA)
  • Beckman Coulter, Inc. (USA)
  • BG Medicine, Inc. (USA)
  • biomérieux SA (France)
  • Boditech Med Inc. (South Korea)
  • Labsystems Diagnostics OY (Finland)
  • LifeSign LLC (USA)
  • LSI Medience Corporation (Japan)
  • Ortho-Clinical Diagnostics, Inc. (USA)
  • Randox Laboratories Ltd. (UK)
  • Response Biomedical Corp. (Canada)
  • Roche Diagnostics (Switzerland)
  • Siemens Healthineers (USA)
  • Merck KGaA (Germany)
3. MARKET TRENDS & DRIVERS
  • The Grim Reality of Mounting Economic and Social Burden of Cardiovascular Disease
  • Population Explosion, Ballooning Geriatric Populace, Longer Life Expectancy Contributing to Rising Tide of CVDs
  • Cardiac Biomarkers Hold the Key to Timely, Accurate Diagnosis & Prognosis
  • Commercialization of Novel Biomarkers to Drive Market Growth
  • Personalized Medicine, Companion Diagnostics Open Up Opportunities for Cardiac Biomarker Developers
  • Cardiac Biomarkers - A Powerful Tool for Patient Triaging
  • Cardiac Biomarkers Market Transitions from Mono-Marker to Multi-Marker Assays
  • Government Support Instrumental for Boosting Market Momentum
  • Secretoneurin Biomarker - a Potential Game Changer for Diagnosis of Cardiac Arrhythmias
  • High-Performance Techniques Drive Biomarker Discovery in Cardiology
  • Biomarkers for Acute Coronary Syndromes (ACS): A Leading Segment
  • Biomarkers - A Promising Diagnostic Tool for ACS
  • Biomarker Discovery for ACS to Undergo Significant Changes
  • Cardiac Biomarker Play Critical Role in Stroke Diagnosis
  • Cardiac Biomarkers to Find a Place in Neonatal Diagnosis and Treatment
  • Specificity, Sensitivity, Side Effects, Cost Concerns Hinder Market Growth
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Cardiac Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Cardiac Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Laboratory Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Laboratory Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Laboratory Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Point-of-Care Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Point-of-Care Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Point-of-Care Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 10: USA Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 11: USA Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: USA 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • CANADA
  • Table 13: Canada Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 14: Canada Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: Canada 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 16: Japan Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 17: Japan Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: Japan 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • CHINA
  • Table 19: China Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: China Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: China 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 22: Europe Current & Future Analysis for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 23: Europe Historic Review for Cardiac Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: Europe 15-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 25: Europe Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: Europe Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: Europe 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 28: France Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 29: France Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: France 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 31: Germany Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Germany Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: Germany 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • ITALY
  • Table 34: Italy Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: Italy Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: Italy 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 37: UK Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: UK Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: UK 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • SPAIN
  • Table 40: Spain Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 41: Spain Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: Spain 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • RUSSIA
  • Table 43: Russia Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 44: Russia Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: Russia 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 46: Rest of Europe Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 47: Rest of Europe Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: Rest of Europe 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 49: Asia-Pacific Current & Future Analysis for Cardiac Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 50: Asia-Pacific Historic Review for Cardiac Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 51: Asia-Pacific 15-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
  • Table 52: Asia-Pacific Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 53: Asia-Pacific Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 54: Asia-Pacific 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • AUSTRALIA
  • Table 55: Australia Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 56: Australia Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 57: Australia 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • INDIA
  • Table 58: India Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 59: India Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 60: India 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • SOUTH KOREA
  • Table 61: South Korea Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 62: South Korea Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 63: South Korea 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
  • Table 64: Rest of Asia-Pacific Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 65: Rest of Asia-Pacific Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 66: Rest of Asia-Pacific 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • LATIN AMERICA
  • Table 67: Latin America Current & Future Analysis for Cardiac Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 68: Latin America Historic Review for Cardiac Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 69: Latin America 15-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
  • Table 70: Latin America Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 71: Latin America Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 72: Latin America 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • ARGENTINA
  • Table 73: Argentina Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 74: Argentina Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 75: Argentina 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • BRAZIL
  • Table 76: Brazil Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 77: Brazil Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 78: Brazil 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • MEXICO
  • Table 79: Mexico Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 80: Mexico Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 81: Mexico 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
  • Table 82: Rest of Latin America Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 83: Rest of Latin America Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 84: Rest of Latin America 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • MIDDLE EAST
  • Table 85: Middle East Current & Future Analysis for Cardiac Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 86: Middle East Historic Review for Cardiac Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 87: Middle East 15-Year Perspective for Cardiac Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
  • Table 88: Middle East Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 89: Middle East Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 90: Middle East 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • IRAN
  • Table 91: Iran Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 92: Iran Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 93: Iran 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • ISRAEL
  • Table 94: Israel Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 95: Israel Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 96: Israel 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
  • Table 97: Saudi Arabia Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 98: Saudi Arabia Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 99: Saudi Arabia 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
  • Table 100: UAE Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 101: UAE Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 102: UAE 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
  • Table 103: Rest of Middle East Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 104: Rest of Middle East Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 105: Rest of Middle East 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
  • AFRICA
  • Table 106: Africa Current & Future Analysis for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 107: Africa Historic Review for Cardiac Biomarkers by Location Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 108: Africa 15-Year Perspective for Cardiac Biomarkers by Location Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 39
Note: Product cover images may vary from those shown
Adroll
adroll